No shock for USCOM
Wednesday, 08 October, 2008
Medical device company USCOM (ASX: USC) has reported that its USCOM 1A device improves management of septic shock in children, according to research published in Pediatrics.
The research was conducted at London's Great Ormond Hospital for Sick Children.
It showed that the USCOM device, which measures cardiac output, allowed earlier and more accurate detection of abnormalities in children admitted to intensive care with septic shock.
The researchers suggested that using USCOM may be an improvement on the current septic shock practice guidelines, and could allow more appropriate prescription of dugs for treatment.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
